CPSI VS LAB Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

CPSI
10/100

CPSI returned -59.89% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

LAB
100/100

LAB returned 45.70% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

CPSI
52/100

11 analysts offer 12-month price targets for CPSI. Together, they have an average target of 0, the most optimistic target put CPSI at 0 within 12-months and the most pessimistic has CPSI at 0.

LAB

"Analyst Price Targets" not found for LAB

Technicals

CPSI
14/100

CPSI receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

LAB
61/100

LAB receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.

Earnings

CPSI
10/100

CPSI has missed earnings 8 times in the last 20 quarters.

LAB
10/100

LAB has missed earnings 8 times in the last 20 quarters.

Profit

CPSI
64/100

Out of the last 20 quarters, CPSI has had 18 profitable quarters and has increased their profits year over year on 7 of them.

LAB
10/100

Out of the last 20 quarters, LAB has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

CPSI
31/100

CPSI has had a lower than average amount of volatility over the last 12 months giving it a score of 30 of 100.

LAB
56/100

LAB has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

Dividend

CPSI
37/100

CPSI's most recent dividend was $0.10 per share, based on a share price of $11.36. It was a payout ratio of 18.57% compared to their total earnings.

LAB

"Dividend" not found for LAB

All score calculations are broken down here to help you make more informed investing decisions

Computer Programs & Systems In Summary

Nasdaq / CPSI
Healthcare
Health Information Services
Computer Programs and Systems, Inc. provides healthcare information technology solutions and services in the United States and the Caribbean nation of St. Maarten. Its software systems include patient management software that enables a hospital to identify a patient at various points in the healthcare delivery system, as well as to collect and maintain patient information throughout the process of patient care; and financial accounting software, which offers business office applications to track and coordinate information needed for managerial decision-making. The company also provides clinical software that automates record keeping and reporting for various clinical functions, including laboratory, radiology, physical therapy, respiratory care, and pharmacy; patient care applications; and enterprise applications that support its products for use in various areas of the hospital, and provide software applications. In addition, it offers Centriq, an intuitive user interface to centralize data from various care areas that provide the end user with a tool to view past and present patient information. Further, the company provides software solutions that promote data-driven clinical and financial outcomes for customers in the post-acute care industry; software application support, hardware maintenance, and education and related services; post-acute care support and maintenance services; revenue cycle management products and services, consulting and business management services, and managed information technology services; patient engagement, and encoder solutions. It serves community hospitals and physician clinics, skilled nursing, and assisted living facilities. Computer Programs and Systems, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.

Standard BioTools Inc. Common Stock Summary

Nasdaq / LAB
Healthcare
Medical - Diagnostics & Research
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.